Hailai has generated hundreds of millions of dollars in B-round financing

Recently, Jiangsu Hailai New Ventures Medical Technology Co., Ltd. (hereinafter referred to as Hailai New Ventures) completed hundreds of millions of yuan B round of financing, the current round of financing by Taifu Capital, Gao Hao Ventures, Junlian Capital Co-led Investment, Taiyi Investment, Next Star Ventures and other old shareholders continue to follow the investment. It is reported that the current round of financing will be mainly used for new adaptive products pipeline development, clinical project acceleration and the introduction of high-end talent team.Following the completion of round A financing at the beginning of this year, in less than a year, Hailai Xinxin has completed two rounds of financing, the cumulative amount of financing of nearly 300 million yuan.Founded in 2016, Hailai is the only company in China to conduct clinical trials of new GBM (glioblastoma), focusing on the development and production of TTF (tumor treatment electric field). Last year, Hailai's new EFE-G100 (adaptive GBM) successfully carried out multi-center clinical work in seven well-known hospitals across the country, marking Hailai's first and the world's second TTF research and development enterprise to enter the multi-center clinical phase. According to Huang Yong, founder and CEO of Hailai, the EFE-G100 program is progressing clinically and the company expects to release key midclinical data by mid-2021.
(
arterial
)